on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Pursues Dual-Track Clinical Strategy for NV-387
NanoViricides, Inc. is advancing its antiviral strategy by targeting both MPox and respiratory viral infections with its lead candidate NV-387. The company aims to address the need for a broad-spectrum oral antiviral treatment using its nano-polymer, micelle technology, which attacks virus particles in the blood.
The company plans a dual-track development for NV-387. The first track targets MPox, related to smallpox, with a Phase II trial approved in Congo. Success there could attract US biodefense funding. The second track involves a basket trial in India in 2026 targeting respiratory viruses, potentially leading to US trials from 2027. With significant market opportunities in RSV and influenza, NanoViricides is positioned for strategic clinical advancement.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news